Trial Profile

A phase 3 study of vepdegestrant in combination plus Pfizer's novel CDK4 inhibitor (PF-07220060) in a first-line Breast Cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2024 According to an Arvinas, Inc. media release, company plans to start this Phase 3 combination trial in the first line setting (anticipated in 2025; pending emerging data and regulatory feedback).
27 Feb 2024 According to an Arvinas, Inc. media release, the company is planning to initiate discussion with regulatory authorities on a new first-line Phase 3 trial of vepdegestrant plus Pfizers novel CDK4 inhibitor (PF-07220060).
11 Dec 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com